中海医药混合A（000878）基金经理为梁静静。 截至发稿，梁静静累计任职时间5年49天，现任基金资产总规模8.11亿元，任职期间最佳基金回 报-12.8%， 任职期间最差基金回报-24.97%。 资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室，成 立日期2013年1月11日，上市日期2022年7月25日，公司主营业务涉及创新药物的研发、生产和销售。主 营业务收入构成为：技术授权和技术合作收入100.00%。 从基金十大重仓股角度 数据显示，中海基金旗下1只基金重仓益方生物。中海医药混合A（000878）二季度持有股数57.84万 股，占基金净值比例为5.99%，位居第八大重仓股。根据测算，今日浮亏损失约116.26万元。 中海医药混合A（000878）成立日期2014年12月17日，最新规模2.3亿。今年以来收益33.46%，同类排 名1598/8194；近一年收益40.59%，同类排名3329/7963；成立以来收益142.14%。 8月27日，益方生物跌5.03%，截至发稿，报37.96元/股，成交3.26亿元，换手率2.00%，总市值219.53亿 元 ...

消息面上，康辰药业将于2025年8月27日召开第二次临时股东大会，审议变更注册资本及修订公司章程 等议案。 截至2025年8月26日收盘，康辰药业股价报50.65元，较前一交易日下跌2.30元，跌幅4.34%。当日成交 额2.40亿元，换手率2.97%。 康辰药业主营业务为创新药物的研发、生产和销售，产品涵盖抗肿瘤、血液系统疾病等领域。公司所属 概念板块包括生物制品、创新药、专精特新等。 风险提示：股市有风险，投资需谨慎。 资金流向方面，8月26日主力资金净流出3071.49万元，近五日累计净流出1.37亿元。 ...

格隆汇8月26日丨君实生物(688180.SH)公布，2025年上半年，公司营业收入为11.68亿元，同比增长 48.64%；归属于上市公司股东的净亏损4.13亿元，上年同期净亏损6.45亿元。公司在创新药物的发现、 研发、生产和商业化等方面取得进展，但尚未实现盈利。公司持续推进在研产品管线，未来将维持研发 投入。 ...

资金流向方面，8月25日主力资金净流入4654.46万元，近五日主力资金累计净流入11273.19万元。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 益方生物-U最新股价为42.18元，较前一交易日上涨0.55%。盘中最高触及43.79元，最低下探41.75元， 成交金额达5.54亿元。 该公司属于生物医药行业，专注于创新药物研发。目前拥有2款已上市产品，1款处于注册临床试验阶段 产品，2款处于II期临床试验阶段产品以及多个临床前在研项目。公司所有在研产品管线均拥有全球权 益。 近期公司发布2025年半年度业绩报告显示，上半年实现营收1916.38万元，同比增长28.85%。公司新申 请发明专利37项，累计获得境内外发明专利授权138项。此外，公司公告拟使用不超过10亿元闲置募集 资金进行现金管理，用于购买安全性高、流动性好的理财产品。 ...

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company announced a three-year strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that the cooperation agreement provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The collaboration is designed to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] Group 2: Project-Driven Model - The cooperation will adopt a project-driven model, focusing on resource sharing and efficient communication as its core framework [1] - This model allows the company to directly utilize the advanced laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets of Sun Yat-sen University Hong Kong Advanced Institute, which are critical for driving innovation in drug research and sustainable development [1] - The board views this strategic partnership as a framework for mutual benefit, contributing to growth and ensuring long-term sustainability [1]

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company has entered into a three-year comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that this cooperation provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The agreement is seen as fair and reasonable, aligning with the overall interests of the company and its shareholders [1] Group 2: Objectives and Framework - The cooperation aims to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] - The project-driven model will focus on resource sharing and efficient communication, allowing the company to utilize the advanced laboratory facilities, animal supply resources, and valuable data assets of the Sun Yat-sen University Hong Kong Advanced Institute [1] - This strategic partnership is expected to create a mutually beneficial framework that supports growth and ensures long-term sustainability, aligning with the company's strategy to advance its pipeline of innovative drugs [1]

Group 1 - The core viewpoint of the articles highlights the performance and developments of Innovent Biologics, including its stock price increase and financial results [1][2][3] - As of August 13, Innovent Biologics' stock rose by 4.3%, reaching a price of 91.05 yuan per share with a trading volume of 300 million yuan [1] - The company focuses on the research, production, and sales of innovative drugs for major diseases such as tumors, autoimmune diseases, metabolic disorders, and ophthalmology, having successfully launched 10 products [1] - Innovent Biologics has 4 products under review, 4 new drug molecules in Phase III or pivotal clinical studies, and 18 new drug candidates in clinical research [1] - By October 2023, the company's patient assistance program has benefited over 170,000 patients, with a total drug donation value of 3.4 billion yuan [1] - For the fiscal year ending 2024, Innovent Biologics reported total revenue of 9.422 billion yuan and a net loss of 94.631 million yuan [1] Group 2 - Innovent Biologics is set to disclose its interim report for the fiscal year 2025 on August 27 [2]

Core Viewpoint - Sanofi Pharmaceutical is a leading biopharmaceutical company in China, focusing on the research, production, and sales of innovative drugs, with a significant market presence in various therapeutic areas [1][2]. Group 1: Company Overview - Sanofi Pharmaceutical has approximately 30 listed products and 31 products in development, with core products leading in market share across various therapeutic areas [1]. - The company possesses comprehensive R&D and CDMO capabilities covering the entire lifecycle of biopharmaceuticals, with six production bases globally [1]. - As of 2023, the CDMO capacity reached 76,000 liters, supported by a network of over 2,600 medical representatives for extensive academic promotion [1]. Group 2: Financial Performance - For the year ending 2024, Sanofi Pharmaceutical reported total revenue of 9.108 billion yuan and a net profit of 2.09 billion yuan [2].

Core Viewpoint - The stock price of Innovent Biologics (01801) experienced a decline of 5.37% on August 11, trading at 86.35 CNY per share with a transaction volume of 999.3 million CNY [1] Company Overview - Innovent Biologics focuses on the research, development, production, and sales of innovative drugs targeting major diseases such as tumors, autoimmune diseases, metabolic disorders, and ophthalmology [1] - The company has successfully launched 10 products, with 4 products currently under review and 4 new drug molecules in Phase III or pivotal clinical studies. Additionally, 18 new drug candidates are in clinical research [1] Financial Performance - As of the 2024 annual report, Innovent Biologics reported total revenue of 9.422 billion CNY and a net profit of -94.631 million CNY [1] - The company's patient assistance program has benefited over 170,000 patients, with a total drug donation value of 3.4 billion CNY [1] Upcoming Events - Innovent Biologics is scheduled to disclose its interim report for the fiscal year 2025 on August 27 [1]

Company Overview - Yifang Biotech-U's stock price on August 6 was 43.20 CNY, unchanged from the previous trading day. The opening price was 43.31 CNY, with a high of 44.71 CNY and a low of 42.60 CNY. The trading volume was 89,000 lots, with a transaction value of 388 million CNY [1]. Industry Focus - Yifang Biotech-U operates in the biopharmaceutical industry, focusing on the research and commercialization of innovative drugs. The company primarily targets the development of targeted therapies for oncology and metabolic diseases [1]. Trading Activity - On August 6, Yifang Biotech-U experienced four block trades totaling 2 million shares, with a transaction amount of 80 million CNY at a price of 40.00 CNY, representing a discount of 7.41% compared to the closing price [1]. - In terms of capital flow, Yifang Biotech-U saw a net outflow of 26.91 million CNY from main funds on August 6, with a cumulative net outflow of 85.91 million CNY over the past five days [1].